Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Squamous Cell Carcinoma of Oral Cavity: early-phase trial registry

1 of 2 indexed Squamous Cell Carcinoma of Oral Cavity trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Squamous Cell Carcinoma of Oral Cavity: 2 US clinical trials tracked, 1 recruiting.

Squamous Cell Carcinoma of Oral Cavity is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Aveta Biomics, running 1 of these trials.

Enrollment posture brief

Registry condition squamous-cell-carcinoma-of-oral-cavity

OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Squamous Cell Carcinoma (th…50%
Open-enrollment share among volume-matched conditions near Squamous Cell Carcinoma of Oral Cavity

Squamous Cell Carcinoma of Oral Cavity lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Squamous Cell Carcinoma of Oral Cavity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Squamous Cell Carcinoma of Oral Cavity is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Top Sponsors

Aveta Biomics 1 trials

Named interventions

Most-linked intervention names on Squamous Cell Carcinoma of Oral Cavity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

APG-157 Drug
1 trials
Pembrolizumab (PD-1 Blocking Antibody) Drug
1 trials
Chemotherapy Prior to RAPA-201 Therapy Drug
1 trials
RAPA-201 Rapamycin Resistant T Cells Biological
1 trials

US sites by state

Facility locations filed on Squamous Cell Carcinoma of Oral Cavity trials. A trial with sites in several states counts in each.

New Jersey 1 trials
Florida 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Squamous Cell Carcinoma of Oral Cavity page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Squamous Cell Carcinoma of Oral Cavity trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Aveta Biomics sponsors the most Squamous Cell Carcinoma of Oral Cavity trials on record, review their full trial history before evaluating a specific study. See Aveta Biomics's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Squamous Cell Carcinoma of Oral Cavity condition card totals 2 registered trials; most-linked intervention APG-157; top US site state New Jersey. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.